Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;7(5):100868.
doi: 10.1016/j.landig.2025.02.008. Epub 2025 Apr 30.

Non-invasive biopsy diagnosis of diabetic kidney disease via deep learning applied to retinal images: a population-based study

Affiliations
Free article

Non-invasive biopsy diagnosis of diabetic kidney disease via deep learning applied to retinal images: a population-based study

Ziyao Meng et al. Lancet Digit Health. 2025 May.
Free article

Abstract

Background: Improving the accessibility of screening diabetic kidney disease (DKD) and differentiating isolated diabetic nephropathy from non-diabetic kidney disease (NDKD) are two major challenges in the field of diabetes care. We aimed to develop and validate an artificial intelligence (AI) deep learning system to detect DKD and isolated diabetic nephropathy from retinal fundus images.

Methods: In this population-based study, we developed a retinal image-based AI-deep learning system, DeepDKD, pretrained using 734 084 retinal fundus images. First, for DKD detection, we used 486 312 retinal images from 121 578 participants in the Shanghai Integrated Diabetes Prevention and Care System for development and internal validation, and ten multi-ethnic datasets from China, Singapore, Malaysia, Australia, and the UK (65 406 participants) for external validation. Second, to differentiate isolated diabetic nephropathy from NDKD, we used 1068 retinal images from 267 participants for development and internal validation, and three multi-ethnic datasets from China, Malaysia, and the UK (244 participants) for external validation. Finally, we conducted two proof-of-concept studies: a prospective real-world study with 3 months' follow-up to evaluate the effectiveness of DeepDKD in screening DKD; and a longitudinal analysis of the effectiveness of DeepDKD in differentiating isolated diabetic nephropathy from NDKD on renal function changes with 4·6 years' follow-up.

Findings: For detecting DKD, DeepDKD achieved an area under the receiver operating characteristic curve (AUC) of 0·842 (95% CI 0·838-0·846) on the internal validation dataset and AUCs of 0·791-0·826 across external validation datasets. For differentiating isolated diabetic nephropathy from NDKD, DeepDKD achieved an AUC of 0·906 (0·825-0·966) on the internal validation dataset and AUCs of 0·733-0·844 across external validation datasets. In the prospective study, compared with the metadata model, DeepDKD could detect DKD with higher sensitivity (89·8% vs 66·3%, p<0·0001). In the longitudinal study, participants with isolated diabetic nephropathy and participants with NDKD identified by DeepDKD had a significant difference in renal function outcomes (proportion of estimated glomerular filtration rate decline: 27·45% vs 52·56%, p=0·0010).

Interpretation: Among diverse multi-ethnic populations with diabetes, a retinal image-based AI-deep learning system showed its potential for detecting DKD and differentiating isolated diabetic nephropathy from NDKD in clinical practice.

Funding: National Key R & D Program of China, National Natural Science Foundation of China, Beijing Natural Science Foundation, Shanghai Municipal Key Clinical Specialty, Shanghai Research Centre for Endocrine and Metabolic Diseases, Innovative research team of high-level local universities in Shanghai, Noncommunicable Chronic Diseases-National Science and Technology Major Project, Clinical Special Program of Shanghai Municipal Health Commission, and the three-year action plan to strengthen the construction of public health system in Shanghai.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests CCL declares honoraria paid to their institution from Boehringer Ingelheim, AstraZeneca, and Sebia. TC is supported by the Clinical Special Program of Shanghai Municipal Health Commission (20224044) and the three-year action plan to strengthen the construction of public health system in Shanghai (2023-2025 GWVI-11.1-28). XY is supported by the Shanghai Municipal Science and Technology Major Project (2021SHZDZX0102). REH is supported by Optos and Novartis. GL is supported by the Australian National Health and Medical Research Council (571012). SS received consulting fees from Bayer, Astella, and Roche; payment or honoraria from Bayer and Roche; and support for attending meetings and travel from Bayer and Roche. AOYL received research grants from Amgen, Bayer, Biogen, Boehringer Ingelheim, MSD, Novo Nordisk, Roche, Health Bureau, and Hong Kong Research Grants Council outside of the submitted work; travelling support from the International Diabetes Federation and the Asian Association for the Study of Diabetes for attending conferences; serves as the President of the Hong Kong Association for the Study of Obesity; and is a council member of Hong Kong Society of Endocrinology, Diabetes and Metabolism. GSWT received research grants from Artificial Intelligence Singapore, the Health Services Research Grant from the National Medical Research Council, the Clinician Scientist Award-Investigator Grant from the National Medical Research Council, and the Large Collaborative Grant from the National Medical Research Council; consulting fees from AbbVie-Allergan, Bayer, Haag-Steit, Leica, Novartis, Roche, Rxilient, and Zeiss; payment or honoraria from Bayer, Haag-Steit, Leica, Novartis, Roche, Rxilient, and Zeiss; and stock from Eyris. C-YC received consulting fees from Medi-Whale. L-LL declares grants paid to institution from AstraZeneca and Abbott; payment or honoraria from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, ZP Therapeutics, Sanofi, Viatris, and Novartis. WJ is supported by the Shanghai Municipal Key Clinical Specialty, Shanghai Research Centre for Endocrine and Metabolic Diseases (2022ZZ01002), and the Chinese Academy of Engineering (2022-XY-08). HL is supported by the Excellent Young Scientists Fund of the National Natural Science Foundation of China (82022012) and the General Fund of the National Natural Science Foundation of China (81870598), and the Innovative research team of high-level local universities in Shanghai (SHSMU-ZDCX20212700). BS is supported by the General Program of the National Natural Science Foundation of China (62272298) and the National Key R & D Program of China (2022YFC2407000). TYW is supported by the National Key R & D Program of China (2022YFC2502800) and the National Natural Science Foundation of China (8238810007); has received consulting fees from AbbVie, Aldropika Therapeutics, Bayer, Boehringer Ingelheim, Carl Zeiss, Genentech, Iveric Bio, Novartis, Opthea, Quaerite Bipharm Research, Plano, Roche, Sanofi, and Shanghai Henlius; and is a co-founder of companies EyRiS and VISRE. All other authors declare no competing interests.

References

Publication types

LinkOut - more resources